Harrison.ai Funding, Investors & Competitors

Harrison.ai has raised $235M across 3 funding rounds, most recently a $112M Series C in February 2025.

Last Harrison.ai funding round

$112M

Series C · Feb 2025

Cumulative funding Harrison.ai raised

$235M

across 3 funding rounds

Key investors in Harrison.ai

  • Blackbird Ventures
  • Horizons Ventures
  • Skip Capital
  • Sonic Healthcare
  • Alpha JWC Ventures
  • Aware Super
  • Wollemi
  • National Reconstruction Fund Corporation

Harrison.ai Overview

About Harrison.ai

Harrison.ai is a Sydney-based global healthtech company that uses AI and partnerships with healthcare specialists to build diagnostic solutions that help address healthcare capacity shortages. Its technology reviews CT scans and X-rays to support the detection and diagnosis of conditions such as cancer, with radiology products under Annalise.ai and pathology products under Franklin.ai. Its proprietary solutions can detect up to 124 findings on chest X-rays and up to 130 findings on non-contrast head CTs, and the software is live in over 1,000 healthcare facilities worldwide, including the UK's National Health Service. It supports the care of more than six million patients a year and holds 12 FDA clearances, one with Breakthrough Device Designation and Medicare reimbursement. Dr Aengus Tran is co-founder and chief executive, with his brother Dimitry Tran. In February 2025 it raised an A$179 million (US$112 million) Series C.


Founded

2018

HQ

AustraliaSydney

Status

Privately held

Customer focus

B2B

Revenue model

Subscription

Harrison.ai Funding History

Harrison.ai has raised a total of $235M across 3 funding rounds.

Harrison.ai's first fundraising round was a $29M Series A in December 2019. The most recent completed round was a $112M Series C in February 2025.

Harrison.ai funding rounds

Harrison.ai funding rounds
DateStageInvestorsRaisedDeal Summary
Feb 2025Series CAware Super (lead); ECP Emerging Growth (lead); Horizons Ventures (lead); Blackbird Ventures; Ord Minnett; Wollemi; Alpha JWC Ventures; National Reconstruction Fund Corporation$112MHarrison.ai, a Sydney-based healthtech company founded in 2018 by brothers Dr. Aengus Tran and Dimitry Tran, develops AI-powered diagnostic support and workflow solutions for radiology and pathology. Its key products include Annalise.ai for radiology, which triages CT scans and X-rays (e.g., identifying up to 124 findings on chest X-rays and securing 12 FDA clearances, including Breakthrough Device Designation for a CT Brain algorithm with Medicare NTAP reimbursement), and Franklin.ai for pathology, with a prostate biopsy product in development for 2025. The solutions address radiologist and pathologist shortages by augmenting human expertise, improving diagnostic accuracy, and enabling remote access, deployed in over 1,000 healthcare facilities worldwide, including the UK's NHS, Hong Kong's public A&E, and Denmark's Health Region Nordjylland. In February 2025, Harrison.ai raised $112 million (AU$179 million) in an oversubscribed Series C funding round, co-led by Aware Super, ECP Asset Management (also noted as Barrack St Investments in some contexts), and Horizons Ventures, bringing total funding to over $240 million following a $92.3 million Series B in November 2021. New investors included Australia's National Reconstruction Fund Corporation, Ord Minnett, and Wollemi Capital Group, with participation from returning investors Blackbird Ventures and Alpha JWC Ventures. The company declined to disclose its valuation. Proceeds will fuel global expansion, particularly establishing a US headquarters in Boston, alongside growth in the UK, EMEA, and APAC, product development (e.g., more AI automation fine-tuned on datasets from 250+ specialist doctors over 240,000 hours), and integration via partnerships like with I-MED Radiology after merging with Annalise.ai. Harrison.ai recently launched Harrison.rad.1, a radiology-specific large language model outperforming GPT-4o and LLaVA-Med. It positions itself in a market strained by global radiologist shortages (e.g., 11 per 100,000 in the US) and healthcare access disparities, aiming to democratize diagnostics. The round is described as one of the largest in medical AI recently, supporting regulatory milestones and international deployments.
Dec 2021Series BHorizons Ventures (lead); I-MED Network Radiology; Blackbird Ventures; Sonic Healthcare; Skip Capital$94MHarrison.ai is a Sydney-based healthtech company developing AI-powered medical diagnostic support and workflow solutions for radiology and pathology, analyzing CT scans, X-rays, and pathology slides to assist clinicians. Founded by brothers Dimitry Tran and Dr. Aengus Tran, it bridges clinical medicine and computer science, with products like Annalise.ai for radiology and Franklin.ai for pathology. The company has expanded globally, serving over 1,000 healthcare facilities and supporting more than six million patients annually, including 1 in 2 Australian radiologists, 45 UK Trusts, and public systems in Hong Kong and Denmark. In November 2021, Harrison.ai raised approximately $92.3 million (AU$93.7 million equivalent) in a Series B round led by Horizons Ventures, with participation from Blackbird Ventures, Skip Capital, I-MED Network Radiology, and Sonic Healthcare. This brought total funding at the time to part of what later exceeded $240 million. Subsequent developments include full acquisition of its 40%-owned subsidiary Annalise.ai in March 2024, leading to a $47.65 million gain. In February 2025, Harrison.ai raised $112 million (AU$178-179 million) in Series C, co-led by Aware Super, ECP, and Horizons Ventures, with Blackbird Ventures returning, totaling over $240 million raised. This funded US expansion, product roadmap, and growth in EMEA and APAC. The company reported $4.75 million in revenue for the financial year ending June 30, 2024, with a net profit driven by the Annalise.ai gain but underlying losses from workforce growth; it has tripled radiology ARR yearly since 2022 under a SaaS model.
Dec 2019Series ABlackbird Ventures (lead); Ramsay Health; Horizons Ventures; Skip Capital$29MHarrison.ai is an Australian AI-powered medtech company developing clinical-grade AI models to enhance diagnostics in radiology, fertility, and other healthcare areas, partnering with organizations like Virtus Health, I-Med, and Ramsay Health Care. Its Series A round on December 9-10, 2019, raised AUD 29 million (approximately $19.8 million USD), led by Blackbird Ventures with participation from Horizons Ventures, Skip Capital, and Ramsay Health Care. The funding supported recruitment of data science and software engineering staff and development of new AI applications, including the Ivy algorithm for embryo selection in IVF, which achieved a 93% success rate in preclinical trials. Harrison.ai's technology now supports over 1,000 healthcare facilities worldwide, aiding six million patients annually, with solutions available to half of Australia's radiologists and significant adoption in the UK, Hong Kong, and Denmark. It has secured 12 FDA clearances and focuses on global expansion, including a US presence in Boston.

Who has invested in Harrison.ai?

12 investors have backed Harrison.ai across its funding rounds, including Blackbird Ventures, Horizons Ventures, Skip Capital, Sonic Healthcare, Alpha JWC Ventures and Aware Super.

Lead investors include Aware Super, ECP Emerging Growth, Horizons Ventures and Blackbird Ventures.


Harrison.ai Investors

Investors in Harrison.ai by funding rounds participated
InvestorHQRoundsRoleFirst check
Blackbird VenturesAustraliaSydney3LeadDec 2019
Horizons VenturesHong KongHong Kong3LeadDec 2019
Skip CapitalAustraliaSydney2ParticipantDec 2019
I-MED Network RadiologyAustraliaSydney1ParticipantDec 2021
Aware SuperAustraliaSydney1LeadFeb 2025
Sonic HealthcareAustraliaSydney1ParticipantDec 2021
Ord MinnettAustraliaSydney1ParticipantFeb 2025
WollemiAustraliaSydney1ParticipantFeb 2025
ECP Emerging GrowthAustraliaAustralia1LeadFeb 2025
Ramsay HealthAustraliaSydney1ParticipantDec 2019

This data is available for Pro users. Sign up to see all 12 Harrison.ai investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Acquisitions by Harrison.ai

Harrison.ai has acquired 1 company to date.

Last acquisition by Harrison.ai was on April 12th 2024. Harrison.ai acquired Annalise.ai for undisclosed valuation.


Latest Acquisitions by Harrison.ai

Annalise.ai
Description
Annalise.ai is a Sydney-headquartered developer of AI-powered radiology software. The Enterprise platform processes chest X-rays to identify over 120 conditions, including pneumonia and fractures, with FDA clearance obtained in 2022. Deployed in hospitals across Australia, the UK, New Zealand, and the US, it enhances diagnostic accuracy and speed for radiologists. Annalise.ai integrates deep learning models trained on millions of imaging studies.
HQ CountryAustralia
HQ City
Sydney
Deal Date12 Apr 2024
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Harrison.ai acquisitions and their M&A valuation multiples.

Start Free Trial

Harrison.ai Competitors

Harrison.ai competitors include listed companies like SAP, Range Intelligent, Tempus AI and iFlytek, and private ones like Scale AI and Helsing.

Public and private companies comparable to Harrison.ai
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
SAPGermanyGermanyPublicly listed$41B$13B$273B6.1x
Scale AIUnited StatesSan Francisco, CAPrivate$2B-$29B14.5x
HelsingGermanyMunichPrivate$502M-$18B35.9x
Range IntelligentChinaChinaPublicly listed$851M$803M$14B14.9x
Tempus AIUnited StatesUnited StatesPublicly listed$1.3B($131M)$14B9.4x
iFlytekChinaChinaPublicly listed$4.1B$468M$14B3.4x

Harrison.ai Public Comps

Harrison.ai is still privately-owned, but its public comps include SAP, CrowdStrike, Salesforce, ServiceNow, Adobe, Moody's, Datadog, Workday, MongoDB and Range Intelligent.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
SAP$41B$13B6.6x6.1x20.9x19.0x
CrowdStrike$4.8B($12M)45.3x38.0x(17454.4x)127.1x
Salesforce$42B$13B5.0x4.6x15.9x10.8x
ServiceNow$13B$2.6B8.3x6.9x42.6x17.8x
Adobe$24B$9.3B4.0x3.6x10.2x7.4x
Moody's$7.7B$3.8B12.1x11.4x24.4x21.8x
Datadog$3.4B($588K)17.7x13.9x(103256.3x)53.1x
Workday$9.6B$1.2B4.9x4.5x40.7x13.5x

This data is available for Pro users. Sign up to see all Harrison.ai competitors and their valuation data.

Start Free Trial

Common questions about Harrison.ai

When was Harrison.ai founded?Harrison.ai was founded in 2018.
Where is Harrison.ai headquartered?Harrison.ai is headquartered in Sydney, Australia.
Is Harrison.ai publicly listed?No, Harrison.ai is a private, VC-backed company.
How much funding has Harrison.ai raised?Harrison.ai has raised $235M across 3 funding rounds.
What was Harrison.ai's last funding round?Harrison.ai's last funding round was a $112M Series C in February 2025, led by Aware Super, ECP Emerging Growth and Horizons Ventures.
Who are Harrison.ai's investors?Harrison.ai's investors include Blackbird Ventures, Horizons Ventures, Skip Capital, I-MED Network Radiology, Aware Super, Sonic Healthcare, Ord Minnett, Wollemi, ECP Emerging Growth, Ramsay Health and 2 others.
Which companies are comparable to Harrison.ai?Companies comparable to Harrison.ai include SAP, Scale AI, Helsing, Range Intelligent, Tempus AI and iFlytek.
How many companies has Harrison.ai acquired?Harrison.ai has acquired 1 company, including Annalise.ai.

See companies similar to Harrison.ai

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial